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Interpreting the association between cannabis
use and increased risk for schizophrenia
Mark Weiser, MD; Shlomo Noy, MD, PhD
atients with schizophrenia use cannabis at
higher rates than those of the general population.
1-3This
has been reported in chronic patients,and other studies
have shown that at the time of the first psychotic episode,
up to 40% of patients already use cannabis.
4,5Although
some authors understood these findings as being due to
self-medication of symptoms of schizophrenia, one
prospective study from 1987 and four more studies pub-
lished in 2002 and 2003 found that persons using cannabis
were at increased risk of later suffering from psychosis
and/or schizophrenia.These findings were interpreted by
some as indicating that cannabis use lies upon a causal
pathway of later psychosis or schizophrenia. In this
paper,we will review these findings,and present an alter-
native explanation for the association between cannabis
use and later schizophrenia.
Review of the data
The first longitudinal study of the relationship between
cannabis use and later schizophrenia utilized data on
cannabis use by 50 000 18-year-old recruits into the
Swedish army,and ascertained hospitalization for schiz-
ophrenia using a hospitalization registry.After a 15-year
follow-up,they found that frequent cannabis use (more
than 50 times in a lifetime) was associated with a sixfold
increased risk for later hospitalization for schizophrenia.
After controlling for possible confounders,the odds ratio
(OR) was 2.3.
6 This same cohort was later reanalyzed
using the same design,
7 27 years after cannabis use had
been ascertained.They found that use of cannabis at least
once by age 18 was associated with increased risk for
later schizophrenia,and,when adjusted for nonpsychotic
diagnosis at conscription,low IQ,poor social integration,
cigarette smoking,and behavioral disturbances in child-
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Recent longitudinal studies from Sweden, the Netherlands,
New Zealand, and Israel report that cannabis use during
childhood and adolescence doubles the risk of later
appearance of psychosis or schizophrenia. These data have
been interpreted as indicating that cannabis has a causal
effect along the pathway to psychosis. In this paper, we
will offer an alternative explanation of these data. Recent
investigations of patients with schizophrenia found
increased density of cannabinoid receptors in the dorso-
lateral prefrontal cortex and the anterior cingulate cortex.
Others reported higher levels of endogenous cannabinoids
in the blood and cerebrospinal fluid of patients; these
findings were independent of possible cannabis use.
Several genetic studies have reported an association
between genes encoding the cannabinoid receptor and
schizophrenia. Thus, an alternative explanation of the
association between cannabis use and schizophrenia
might be that pathology of the cannabinoid system in
schizophrenia patients is associated with both increased
rates of cannabis use and increased risk for schizophrenia,
without cannabis being a causal factor for schizophrenia.  
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hood,the OR was 1.5.Frequent cannabis use (more than
50 times in a lifetime) was associated with a threefold
increased risk for schizophrenia.
The Netherlands Mental Health Survey and Incidence
Study (NEMESIS)
8 assessed a random sample of 4104
persons aged 18 to 64 and followed them for 3 years.
Compared with persons not reporting cannabis use at
baseline, persons using cannabis at baseline were 2.8
times more likely to manifest psychotic symptoms at fol-
low-up, after controlling for age, gender, ethnic group,
education,unemployment,single marital status,urbanic-
ity,and discrimination.A dose–response relationship was
present,with the highest risk (adjusted OR=6.8) for the
highest level of cannabis use.
The Dunedin Multidisciplinary Health and Development
Study
9 examined 759 persons from a general population
birth cohort of individuals born in Dunedin, New
Zealand.They assessed cannabis use at ages 15 and 18,
and presence of schizophreniform disorder was ascer-
tained at age 26. Their results indicated that use of
cannabis at age 15 was associated with higher incidence
of schizophreniform disorder (OR=3.1) after controlling
for social class and presence of psychotic symptoms at
age 11. Finally, in a similar longitudinal, historical-
prospective design, 50 413 male adolescents who had
been suspected of having behavioral or personality dis-
turbances were asked about cannabis use in the Israeli
draft board.
10 Self-reported drug use was associated with
a twofold increase in later hospitalization for schizo-
phrenia,after adjustment for intellectual and social func-
tioning,and the presence of a nonpsychotic psychiatric
diagnosis at the draft board assessment.
Inferring causality from epidemiological data is often
problematic,and the classic criteria suggested by Hill
11
are often used when deliberating over these issues.The
Hill criteria include strength,consistency,specificity,bio-
logical gradient,temporality,coherence,and plausibility.
Regarding the strength of the association, an OR of 2,
especially for a relatively rare illness like schizophrenia,
does not represent a particularly strong association,but on
the other hand,many other,well-established risk factors
for illness have similar ORs,such as cigarette smoking and
later lung cancer,
12 and hypercholesterolemia and later
atherosclerotic cardiovascular disease.
13The data across
these different studies are remarkably consistent,using dif-
ferent patient populations and different research method-
ologies,with very similar results.Several of the studies on
the topic examined the specificity of the relationship
between cannabis use and schizophrenia:Zammit et al,
7
Van Os et al,
8 and Arseneault et al
9 controlled for use of
other drugs in their analyses,thus addressing the issue of
specificity of exposure.Van Os et al
8 found that cannabis
use was not associated with other psychotic disorders,
whereas Arseneault et al
9 and Weiser et al
10 did not find an
association between cannabis use and later depression,
indicating specificity of outcome.
The presence of a biological gradient is supported by the
presence of a dose–response relationship,with increas-
ing amounts of cannabis used associated with increasing
risk for psychosis
8 or schizophrenia.
6,7As these are all lon-
gitudinal studies,which assessed cannabis use at baseline
and ascertained later appearance of psychotic illness,the
temporality criterion is clearly met.Coherence refers to
how the proposed association relates to the generally
known facts regarding the illness.This seems problem-
atic,as the use of cannabis has increased tremendously
over the past four decades: according to the National
Survey on Drug Use and Health (NSDUH,previously
known as the National Household Survey on Drug Use),
“… the percentage of young adults aged 18 to 25 who
had ever used marijuana was 5.1% in 1965,but increased
steadily to 54.4% in 1982.Although the rate for young
adults declined somewhat from 1982 to 1993,it did not
drop below 43% and actually increased to 53.8% by
2002.”
14This represents an increase of approximately 10-
fold in the use of cannabis in adolescents; if cannabis
does, in fact, cause psychotic illness, then one would
expect that the prevalence of psychotic illness would
increase in parallel to the greatly increased use of the
“causative” substance in the Western world. This is
clearly not the case,as there are reports both of increases
and decreases in the prevalence of schizophrenia
15-18 in
the Western world, with no clear evidence of a signifi-
cantly increased prevalence that would be expected if the
use of a causative substance increased 10-fold.
In addressing this issue, some authors have suggested
that cannabis use in early adolescence is associated with
particularly strong association with later psychotic illness,
and that this is a fairly new phenomenon,in that cannabis
use among adolescents under the age of 16 years in the
USA has appeared only since the early 1990s.
12This indi-
cates that the hypothesized effect of cannabis use on the
prevalence of schizophrenia will only be observed in the
years to come.However,data from the NSDUH
14 indi-
cate that there has been a significant increase in cannabis
use in this age group as well:the number of 12 to 17 yearCannabis use:a causal factor for schizophrenia? - Weiser and Noy Dialogues in Clinical Neuroscience - Vol 7 . No.1 . 2005
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olds using cannabis for the first time rose from 9.2 per
1000 in 1965, to 58.2 per 1000 in 1980, and to 83.2 per
1000 in 1996. Thus, there has been a very significant
increase in cannabis use in young adolescents as well,
which would be expected to lead to an increase of schiz-
ophrenia in the population, if cannabis were in fact
causative. Regarding biological plausibility, there are
some reports on changes in the endogenous cannabinoid
system in schizophrenia,which might be related to the
effects of cannabis on the brains of patients;this will be
discussed in greater detail below.
To summarize,based on commonly accepted criteria for
causality,there seems to be a reasonable case to be made
for cannabis causing schizophrenia;this is clearly delin-
eated in a recent review.
19
Alternative explanation
We would like to present an alternative explanation of
these findings,based on the work of others and ourselves
on premorbid adjustment and schizophrenia. Several
prospective longitudinal studies suggest that adolescents
who manifest abnormal behavior or personality traits
may be at high risk of later manifesting schizophrenia as
adults. Persons with obsessive-compulsive disorder
(OCD),social phobia,and panic attacks examined in the
Epidemiologic Catchment Area (ECA) study
20 were at
increased risk for future schizophrenia.The Minnesota
Multiphasic Personality Inventory (MMPI) traits of
depression,anxiety,internalized anger,social alienation,
and withdrawal are associated with increased risk for
future schizophrenia.
21A follow-up study of conscripts
screened by the Swedish army found that 18 year olds
with personality disorders or neurosis were at increased
risk for future schizophrenia, and a study on a British
birth cohort reported that neuroticism at age 16 was asso-
ciated with increased risk for later schizophrenia.
22A sep-
arate set of studies indicates that these nonpsychotic psy-
chiatric disorders are associated with increased rates of
cannabis use.
23The National Comorbidity Survey
24 found
that 90% of respondents with cannabis dependence had
a lifetime mental disorder,compared with 55% without
cannabis dependence. Antisocial personality disorder
(OR=11.2) and conduct disorder (OR=6) had the
strongest associations with cannabis dependence, fol-
lowed by anxiety (OR=2.6) and mood disorders
(OR=2.0). In Australian adolescents aged 13 to 17,
25
cannabis use was associated with depression (OR=3.1)
and conduct problems (OR=3.6).
These data raise the possibility that future schizophrenia
patients have increased rates of premorbid behavioral
disturbances and psychiatric diagnoses,and these,in turn,
are associated with increased rates of cannabis use.One
might say that future patients are using cannabis as self-
medication of premorbid behavioral disturbances and
psychiatric diagnoses.
These epidemiological data are supported by studies
indicating that similar neuropathologies might be
involved in both cannabis use and schizophrenia, and
other reports indicating that patients with schizophrenia
have impairments in the endogenous cannabinoid sys-
tem. Research on the neurobiology of drug abuse and
schizophrenia
26 indicates that the mesolimbic dopamine
system is involved in both cannabis abuse
27 and schizo-
phrenia.
28 Furthermore,dysregulation in cortical,tempo-
ral, limbic, and mesoaccumbens circuits is implicated
both in schizophrenia
29 and in substance abuse disor-
ders,
30 and behavioral disturbances modulated by the hip-
pocampus and mediated by the nucleus accumbens are
associated with schizophrenia
31 and with cannabis abuse.
32
Thus,it is plausible that developmental neuropathology
in hippocampal and prefrontal cortical pathways con-
tributes to vulnerability to both schizophrenia and
cannabis use, via dysfunctional interactions with the
nucleus accumbens. More recent reports indicate that
specific receptors exist in the brain that recognize
cannabinoids,and a series of endogenous cannabinoids
have been discovered that act as ligands for these recep-
tors.The density of these receptors has been found to be
increased in the anterior cingulate cortex
33 and dorsolat-
eral prefrontal cortex
34 in schizophrenia patients com-
pared with controls.These findings were independent of
cannabis use.Two studies on the genetics of the central
CB1 cannabinoid receptor have reported an association
between polymorphisms of the CNR1 gene and schizo-
phrenia.
35,36 Levels of the endogenous cannabinoid anan-
damide have been found to be elevated in the blood
37
and cerebrospinal fluid
38,39 of patients with schizophrenia,
independent of cannabis use.All of these findings point
to possible structural and functional impairments in the
endogenous cannabinoid system in schizophrenia
patients.On this basis,we suggest that these impairments
in the endogenous cannabinoid system might be related
to the slightly increased propensity of future schizophre-
nia patients to smoke cannabis,and are also associated
with increased risk for schizophrenia.Clinical research
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Conclusion
The data presented above indicate that:(i) future schiz-
ophrenia patients have premorbid behavioral abnormal-
ities that might increase their propensity to use cannabis;
(ii) cannabis use and schizophrenia might be the mani-
festations of a common brain pathology;and (iii) schizo-
phrenia patients have dysfunctions of the endogenous
cannabinoid system independent of cannabis use.The
nature of the association between cannabis use and schiz-
ophrenia awaits further elucidation from research into
the biology of schizophrenia, but, at this point in time,
based on the available evidence,it seems premature to
claim that cannabis use causes schizophrenia. ❏
This study was supported by the Stanley Medical Research Institute and by
NARSAD 
La interpretación de la asociación entre el
uso de cannabis y el aumento del riesgo de
esquizofrenia
Estudios longitudinales recientes realizados en
Suecia, Holanda, Nueva Zelandia e Israel señalan
que el empleo de cannabis durante la niñez y la
adolescencia duplica el riesgo de aparición posterior
de psicosis o de esquizofrenia. Estos resultados se
han interpretado como indicadores de que el can-
nabis tendría un efecto causal en la vía que lleva a
la psicosis. En este artículo se ofrecerá una explica-
ción alternativa de estos resultados. Investigaciones
recientes en pacientes con esquizofrenia encontra-
ron un aumento en la densidad de los receptores de
cannabinoides en la corteza prefrontal dorsolateral
y la corteza cingulada anterior. Otros trabajos han
informado acerca de altos niveles de cannabinoides
endógenos en sangre y líquido céfalo-raquídeo de
pacientes y estos resultados fueron independientes
del posible uso de cannabis. Varios estudios gené-
ticos han dado cuenta de una asociación entre
genes que codifican el receptor de cannabinoides
y la esquizofrenia. De tal forma que una explicación
alternativa para la asociación entre el empleo de
cannabinoides y la esquizofrenia podría ser que la
patología del sistema cannabinoide en pacientes
esquizofrénicos se relacione tanto con un aumento
en el porcentaje de uso de cannabis como con un
incremento en el riesgo de tener esquizofrenia, sin
que el cannabis sea un factor causal para la esqui-
zofrenia.
Interprétation de l’association entre 
consommation de cannabis et augmentation
du risque de schizophrénie
De récentes études longitudinales issues de Suède,
des Pays-Bas, de Nouvelle-Zélande et d’Israël rap-
portent que l’utilisation de cannabis pendant l’en-
fance ou l’adolescence double le risque d’appari-
tion ultérieure de psychose ou de schizophrénie.
Ces résultats ont été interprétés de façon à suggé-
rer que le cannabis a un effet causal pouvant mener
à une psychose. Dans cet article, nous allons pro-
poser une autre interprétation de ces données. Des
travaux récents sur des patients atteints de schizo-
phrénie ont mis à jour une augmentation de la
densité des récepteurs cannabinoïdes dans le cor-
tex préfrontal dorsolatéral et dans le cortex cingu-
laire antérieur. D’autres recherches ont indiqué des
concentrations plus élevées de cannabinoïdes endo-
gènes dans le sang et le liquide cérébrospinal des
patients ; ces constatations étaient indépendantes
d’un usage éventuel de cannabis. Plusieurs études
génétiques ont rapporté une association entre les
gènes codant le récepteur cannabinoïde et la schi-
zophrénie. Ainsi, une autre explication de l’asso-
ciation entre l’usage du cannabis et la schizophré-
nie pourrait être que la pathologie du système
cannabinoïde chez les patients atteints de schizo-
phrénie est associée à la fois à l’augmentation des
taux d’utilisation du cannabis et à l’augmentation
du risque de schizophrénie, sans que le cannabis
soit le facteur causal de la schizophrénie.Cannabis use:a causal factor for schizophrenia? - Weiser and Noy Dialogues in Clinical Neuroscience - Vol 7 . No.1 . 2005
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